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ABSTRACT 
Objective 
A large proportion of paediatric patients with attention-deficit/hyperactivity disorder (ADHD) have associated sleep 
problems which not only affect the child’s well-being but also impact family functioning. Management of sleep 
problems is consequently an important aspect of overall ADHD management in paediatric patients. Although some 
drugs are being used off-label for the management of paediatric insomnia, there is scant clinical evidence supporting 
their use. Our aim was to identify and assess the quality of published studies reporting the safety, tolerability and 
efficacy of drugs used for treating behavioural insomnia in children with ADHD.  
Method 
After an initial screen to determine which drugs were most commonly used, we conducted a systematic review of 
English-language publications from searches of PubMed, EMBASE, PsychInfo and two trial register databases to 
February 2017, using keywords clonidine, melatonin, zolpidem, eszopiclone, L-theanine, guanfacine, ADHD, sleep 
disorder and children. For quality assessment of included studies, we used the CONSORT checklist for randomized 
control trials (RCTs) and the Downs and Black checklist for non-RCTs. 
Results 
Twelve studies were included. Two case series for clonidine, two RCTs and four observational studies for melatonin 
and one RCT each for zolpidem, eszopiclone, L-theanine and guanfacine. Of the 12 included studies, only one on 
eszopiclone scored excellent. The quality of the rest of the studies varied from moderate to low. For clonidine, 
melatonin and L-theanine, improvement in sleep-onset latency and total sleep duration, were reported; however, 
zolpidem, eszopiclone and guanfacine failed to show any improvement when compared with placebo. Clonidine, 
melatonin, L-theanine, eszopiclone and guanfacine were well tolerated with mild to moderate adverse events except 
for zolpidem which was associated with neuropsychiatric adverse effects.  
Conclusion 
There is generally poor evidence for prescribing drugs for behavioural insomnia in children with ADHD. Further 
controlled studies are warranted.  
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1 INTRODUCTION 
Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder affecting 
children and adolescents. It is characterized by age-inappropriate and persistent symptoms of inattention and/or 
hyperactivity/impulsivity 1. In a recent meta-analysis, the overall pooled prevalence of ADHD was estimated to be 
7.2% 2. Among the conditions associated with ADHD, sleep problems have generally received inadequate attention 
in the past but are currently the focus of increasing interest.  
Corkum et al. 3 concluded that sleep problems had been reported in about 25-50% of children with ADHD. The 
sleep problems reported in children with ADHD include disturbances in sleep quality or quantity, restless leg 
syndrome (RLS), periodic limb movement (PLM) and sleep disordered breathing (SDB) 4. Among these the most 
common problems include difficulty initiating sleep, maintaining sleep (recurrent waking or restless sleep) and early 
morning awakening with inability to return to sleep 4-7.  There is a relationship between sleep and ADHD symptoms, 
which seem to overlap with very little separation. It is currently not clear whether sleep disturbances are elemental to 
ADHD or sleep disorders cause ADHD-like symptoms. Even though the causes of ADHD-associated sleep 
problems seem to be complex and multifactorial, possible factors include: adverse effects of drugs taken for treating 
ADHD such as stimulant medication 8, clinical correlates stemming from core ADHD symptoms (e.g., hyperactivity 
at night leading to difficulty falling asleep), psychiatric comorbidities (eg bedtime behavioural issues arising from 
associated conduct disorder), or a combination of these factors 9-12. 
In a meta-analysis of subjective and objective sleep studies, Cortese et al. 13 showed that children with ADHD were 
significantly more impaired than controls in most of the parent-reported (subjective) parameters such as bedtime 
resistance, sleep-onset difficulties, daytime sleepiness and in some of the actigraphic/polysomnographic-measured 
(objective) sleep items, such as, sleep-onset latency and number of stage shifts in total sleep time. Using the 
subjective parameters, most of the studies have reported sleep disturbances such as early and middle insomnia, 
nocturnal awakening, short sleep time, restless sleep and daytime sleepiness in children with ADHD 14-16.  Even 
though there is poor understanding of the relationship between sleep and ADHD symptoms, from a clinical 
standpoint, sleep disturbances associated with ADHD are very relevant since they can cause worsening of ADHD 
symptoms, leading to an increase in disruptive behaviour 17. Sleep disturbances can not only have a significant 
impact on the quality of life of the child with ADHD but can also cause parental stress, disturbed caregiver mental 
health and disorganized family functioning 16. Because of these issues, treatment of comorbid sleep disturbances is 
often a very important aspect of ADHD management. There is increasing awareness of the importance of 
behavioural insomnia treatments in children with ADHD. In one of the Australian Paediatric Research Network 
Surveys to document the management practices by Australian Paediatricians for paediatric sleep disturbances, 
89.1% of paediatricians prescribed melatonin for paediatric sleep disturbance 18. Out of these, 54.5% prescribed it 
for sleep problems in children with ADHD. Another study showed that almost one-quarter (22%) of the children 
with ADHD were prescribed sleep medication, with 14% and 9% taking clonidine and melatonin, respectively 19. An 
anonymous questionnaire survey of members of the British Association for Community Child Health (BACCH) and 
the British Academy of Childhood Disability (BACD) was carried out in the UK to examine prescribing practices 
for melatonin in children 20. Responses to questionnaires showed that sleep-onset difficulties (39%) and night-
waking (12%) were the most frequent indications reported for melatonin use, with autism (68%) and ADHD (44%) 
being the most frequent clinical diagnoses.  
 
A panel of experts in ADHD and sleep concluded that non-pharmacological interventions, which include sleep 
hygiene and behavioural interventions, should be the first-line management 10, 21. The National Institute for Health 
and Care Excellence (NICE) also recommends non-pharmacological interventions such as good sleep hygiene or 
behavioural therapy 22. If non-pharmacological treatments fail, pharmacological treatments may need to be 
considered. Drugs that have been used in clinical practice include clonidine, melatonin, antidepressants, such as 
trazodone and mirtazapine, hypnotics, such as zolpidem, and antihistamines 11. However, evidence supporting these 
treatments remains limited 23. Furthermore, none of these drugs has been approved for treating sleep disturbances in 
children with ADHD 24. In addition, a drug closely related to clonidine, guanfacine, which, like clonidine, is also an 
α-2 receptor agonist, is becoming more widely used for the treatment of ADHD. Somnolence is a major side-effect 
of guanfacine; it remains to be seen what role this drug will have in the management of sleep problems in children 
with ADHD 25. 
 
Clonidine and guanfacine have been approved by FDA for ADHD treatment. However there are no approved 
treatments, either prescribed or over-the-counter preparations for managing sleep disturbances such as behavioural 
insomnia in these children, as compared to those in general paediatric populations 4, 26, 27. Despite the widespread use 
of these unapproved agents to aid sleep in children with ADHD, few data exist on their safety, tolerability and 
efficacy. Furthermore, the methodological quality of the limited information available has not been assessed. 
This paper provides a systematic review and methodological quality assessment of published studies on the safety, 
tolerability and efficacy of the most commonly used drugs for treating behavioural insomnia associated with ADHD, 
focusing on sleep-onset insomnia, total sleep duration and number of awakenings during the night.  
 
2 METHODS 
The systematic review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) Statement 28.   
 
2.1 Systematic Search 
An initial search was performed in PubMed using the search terms (adhd [ti] OR attention deficit [ti]) (sleep [ti] OR 
insomnia [ti]) and similar searches were carried out in Embase and PsycINFO. This initial search, identified reports 
on the following drugs having been used for the treatment of sleep problems in individuals with ADHD: clonidine 29, 
melatonin 30, eszopiclone 31, zolpidem 32, L-theanine 33 and guanfacine 34. Clonidine and guanfacine are established 
drugs for treating ADHD 35-37. Sedative effects of these drugs becomes advantageous for the management of sleep 38, 
39. Melatonin is currently the most commonly used medication (hormone) for sleep problems in children 40. The "z-
drugs", such as eszopiclone and zolpidem are specifically indicated for sleep problems in adults; 41-43 however, their 
safety and efficacy in patients below the age of 18 have not been established. L-theanine (5-N-ethyl-L-glutamine) is 
a herbal remedy that is a constituent of teas, including both green and black tea; it is promoted as inducing relaxation, 
although the evidence for this appears to be limited 44, 45.  
 
The search strategy was then refined to focus on these six drugs and extra databases were searched. A systematic 
literature search of PubMed, EMBASE and PsycINFO was conducted using keywords, MeSH and Emtree terms. 
The following search terms were used: (ADHD OR attention deficit hyperactivity disorder OR neurodevelopmental 
disorder) AND (sleep OR insomnia) AND (clonidine OR melatonin OR eszopiclone OR zolpidem OR L-theanine 
OR guanfacine) AND (child OR children OR youth OR adolescent OR paediatric). The U.S. National Institutes of 
Health Trial Register (http://www.ClinicalTrials.gov) and the World Health Organization International Clinical 
Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/en/) were also searched to identify potentially relevant 
studies. All databases were searched for studies from their inception to February 2017. Duplicates were removed. 
Titles, abstracts and the content of the articles were screened to determine suitability for inclusion. References in the 
retrieved articles were also searched to identify any additional studies missed in the electronic search. 
 
2.2 Inclusion criteria 
Observational and interventional studies investigating the effects of clonidine, melatonin, zolpidem, eszopiclone, L-
theanine and guanfacine on behavioural insomnia in children with ADHD were included. ADHD was defined in the 
papers under review according to the following criteria: Diagnostic and Statistical Manual (DSM) of Mental 
Disorders (version DSM-III-R, DSM-IV or DSM-IV-TR) or guidelines of the American Academy of Child and 
Adolescent Psychiatry or through the Diagnostic Interview Schedule for Children Version IV and parents and 
teachers report on the child symptom inventories 46-52. As recommended by the Cochrane group, in order to ensure 
high levels of methodological adequacy and to avoid the inevitable bias caused by dependence on investigators 
agreeing to provide data from unpublished studies, only published, peer-reviewed studies were included. 
 
2.3 Exclusion criteria  
1) Single case reports. 
2) Medications used in other medical conditions, including developmental disabilities or other 
neurodevelopmental disorders such as autism, unless the subjects also had ADHD.  
3) Mixed neurodevelopmental disorder subject groups; for example, autism spectrum disorder with and 
without ADHD, for which separate results for each subgroup were not provided.  
4) Publications in languages other than English. 
5) Non peer-reviewed publications (such as conference proceedings). 
6) Animal studies. 
 
2.4 Data extraction  
Two authors selected the studies on the basis of the inclusion/exclusion criteria and extracted data including: study 
design, ADHD medication use, patient age, drug, sleep hygiene information and outcome measures of safety, 
tolerability and efficacy. Any disagreement was resolved by consensus. 
 
2.5 Assessment of study quality  
The methodological quality for the included randomised controlled trials (RCTs) was assessed using the CONSORT 
statement 53, 54. The checklist was divided into domains: title and abstract, introduction, methods, randomization, 
results, discussion and other information. The scores for each domain were summed to obtain the overall score. The 
methodological quality for observational studies was assessed using the Downs and Black scale for observational 
studies 55.  
 
Two authors appraised each RCT and observational study independently. Assessment was conducted independently 
and cross-checked. The discrepancies were resolved by consensus. A CONSORT score from a maximum score of 
25 was calculated by analysing each item in the checklist. Some of the items in the checklist contain two parts: “a” 
and “b”. Each CONSORT checklist item as a whole was scored as 1 if present in the appraised study or 0.5 if only 
one part of the item was addressed. For observational studies, the quality score was calculated from a maximum 
score of 28. The checklist is divided into different domains: reporting, external validity, internal validity and power. 
The scores for each domain are summed to obtain the overall score. The Downs and Black checklist has several 
domains: reporting, external validity, internal validity and power, containing 27 items. Each item was scored 1 if the 
answer was “yes” and 0 if the answer was “no” or unable to determine (UTD) except for one of the reporting 
subscales which was scored as 0 or 2. The scores were then added for total quality score. We adopted the following 
quality levels based on previous literature: excellent (>20 items), good (13-19) and poor (≤12) for CONSORT 56 and 
excellent (26-28), good (20-25), fair (15-19) and poor (≤14) for Downs and Black assessment 57-59.  
 
3 RESULTS 
3.1 Search Results and general characteristics of included studies 
The PRISMA flow diagram of the review is shown in Figure 1. The electronic database yielded a total of 702 
records. Ten additional records were identified from the references. Titles and abstracts were screened, and the full 
texts of 23 articles were further screened. Twelve studies, either observational studies or RCTs, met the inclusion 
criteria for this systematic review.  
For clonidine, two case series were identified 29, 60. For melatonin, three RCTs 30, 61, 62, and three observational 
studies 63-65 met the inclusion criteria. Two studies 62, 66 had the same data for melatonin, hence only one was 
included. For zolpidem, eszopiclone, L-theanine and guanfacine, one RCT for each met the inclusion criteria 31-34. 
Characteristics of the included studies are shown in Table 1. 
 
3.2 Quality Assessment  
RCTs 
The CONSORT checklist was used for quality assessment of RCTs as shown in online resource 1. The scores for 
each study were as follows. For eszopiclone, Sangal et al. 31: 21.5, (excellent quality). For melatonin, Weiss et al. 61: 
15.5 and Van der Heijden et al. 30: 18.5 (both good quality) and Mohammadi et al. 62: 10.5 (poor quality). For 
zolpidem, Blumer et al. 32: 17.5 (good quality).  For L-theanine, Lyon et al. 33: 9.5 (poor quality). For guanfacine, 
Rugino 34: 17.5 (good quality). The individual scores for each study are detailed in Table 2.  
Observational Studies 
The Downs and Black checklist was used for observational studies as shown in online resource 2. The scores for 
each study were as follows. For clonidine, Wilens et al. 29: 4 and Prince et al. 60: 13, (poor quality). For melatonin, 
Tjon Pian Gi et al. 63: 11, Ayyash et al. 65: 14,  (both poor quality) and Hoebert et al. 64: 22 (good quality). The 
quality of the results is detailed in Table 3. 
The results from both RCTs and observational studies indicated that the quality of most of the available studies for 
the drugs treating behavioural insomnia in children with ADHD is not very high.  
 
3.3 Efficacy of the Pharmacological agents  
Please note that, for all the studies in this section, where specific measures have been used or statistically significant 
differences have been found, these have been stated in the text that follows. Further information, for example on the 
quality of the studies, is available in the tables and elsewhere in the paper but, to avoid unnecessary duplication, has 
not been repeated here. 
 
3.3.1 Clonidine 
Based on a case series of more than 100 children with ADHD, Wilens et al. 29 stated that the beneficial effects of 
clonidine on sleep commenced within 30 minutes and persisted until morning. Both children and parents reported 
(subjective measure) favourable comments regarding clonidine treatment taken at bedtime, with overall 
improvement of sleep problems: less oppositional behaviour in the context of sleep activities, reduced sleep latency, 
less sleep restlessness, increased number of hours slept and improved morning awakening.  
Prince et al. 60 carried out a systematic chart review of 62 children with ADHD and sleep problems, such as 
difficulty falling asleep, restless sleep and difficulty awakening. Subjective measures such as clinical global 
assessment of sleep severity (CGS) and of improvement (CGI) were used to rate sleep, with scores which ranged 
from 1-7. 53 out of 62 (85%) of the children and adolescents had CGI values of 1 (very much improved; n=19) or 2 
(much improved; n=34).  
 
3.3.2 Melatonin 
Weiss et al. 61 evaluated the efficacy of sleep hygiene and melatonin for initial insomnia in children with ADHD in a 
RCT. Attention to sleep hygiene resulted in significant improvement in mean sleep-onset latency (SOL) from 
baseline (91.7 min reported subjectively by somnolog which were parents completed sleep logs  and 98.1 min 
reported objectively by actigraphy) to 69.3 min by somnolog and 73 min by actigraphy (in five subjects); i.e. mean 
sleep-onset latency was improved (decreased) by 22.4 min by somnolog and 15.1 min by actigraphy. For non-
responders to sleep-hygiene measures, the mean Somnolog SOL (documentation from parents for the amount of 
time between when the child was put to bed and when he/she fell asleep) for melatonin was 46.4 min (standard 
deviation (SD)=26.4) and for placebo was 62.1 min (SD=26.6). Two-sample t-tests comparing the mean period 
difference between sleep latencies and crossover treatment differences for melatonin vs placebo indicated a 
significant difference between these sleep latencies (p<0.01) and a significant period effect (period difference in two 
crossover-treatment sequences) (p<0.05). For total night-time sleep, more time asleep (15 min) was evident during 
melatonin treatment, (p<0.01) on somnolog monitoring, whereas actigraphic 67 analysis did not show a significant 
treatment difference. Open-label follow-up did not show a significant improvement in SOL; however, the 
improvement in sleep duration by 23 minutes continued, (p<0.01) with the melatonin treatment. 
 
Van der Heijden et al. 30 investigated the efficacy of melatonin on sleep objectively with actigraphy and with dim 
light melatonin onset (DLMO) using saliva samples and also with assessments of behaviour, cognition and quality 
of life using different questionnaires in an RCT. There was an increase in mean total time asleep of 19.8 ± 61.9 
minutes with melatonin and a decrease of 13.6 ± 50.6 minutes with placebo (p=0.01). Compared with placebo, the 
melatonin group had a statistically significant decrease in sleep latency (p=0.001), increase in sleep efficiency 
(p=0.01), and decrease in nocturnal restlessness (p=0.03). The saliva samples of melatonin-treated children showed 
an advance in DLMO of 44.4 ± 67.9 minutes compared with a delay of 12.8 ± 60.0 minutes in children receiving 
placebo (p<0.0001). No statistically significant improvement was found in problem behaviour, cognitive ability or 
quality of life scores assessed on the different questionnaires.  
Mohammadi et al. 62 in another RCT, subjectively studied the effects of melatonin on sleep, and features of 
hyperactivity and attention deficit in children taking methylphenidate (Ritalin). The mean sleep latency (in minutes) 
decreased with melatonin. The mean latency at baseline for placebo was 21.37 and at eight weeks was 26.37. The 
mean latency at baseline for melatonin was 23.15 and at eight weeks was 17.96. The mean total sleep duration (in 
hours) increased with melatonin. The mean sleep duration at baseline for placebo was 8.77 and at eight weeks was 
8.27 (slight deterioration). The mean sleep duration at baseline for melatonin was 8.0 and at eight weeks was 8.51 
(improvement). The mean sleep latency and total sleep disturbance scores were reduced in the melatonin group, 
while the scores increased in the placebo group but no statistically significant differences were found for the two 
groups during the study period.  
Tjon Pian Gi et al. 63 demonstrated the effect of melatonin on sleep-onset insomnia in children with ADHD on 
methylphenidate in an observational study through subjective measures. Short-term (1-4 weeks) and long-term (after 
3 months) effects showed significant improvement in sleep latency, varying between 15-240 minutes and between 
15-64 minutes, respectively. Relapse of sleep-onset insomnia occurred when melatonin treatment was forgotten 
during the study and after end of the study but improved when the melatonin was restarted. 
Hoebert et al. 64  in a follow-up study, aimed to determine the long-term effectiveness and safety of melatonin 
therapy through subjective measures, along with the relapse rate of sleep-onset insomnia (SOI) after discontinuing 
melatonin treatment. Twenty two children (23.4%) discontinued melatonin completely because of either total 
improvement of SOI (8), adverse events (3), initiative of treating physician (2), concerns about long-term treatment 
effects (2), refusal by child (1), lack of positive effect of therapy (3), melatonin therapy substituted by light therapy 
(1) and for unknown reason (2). DLMO, as in the initial study, was assessed at the baseline and on the first evening 
of the fourth week. The mean (± SEM) pre-treatment DLMO time of the eight children who discontinued melatonin 
completely because of improvement of SOI was 20:21 ± 0.25 hrs, while this was 20:41 ± 0.06 hrs in the remaining 
subjects, who discontinued treatment due to other reasons (p=0.413, ES = -0.09). The mean pre-treatment DLMO of 
the 11 children (20:11 ± 0.15 hrs) who used melatonin occasionally was earlier as compared to DLMO in the 61 
children (20:48 ± 0.007 hrs ) who took melatonin daily (p=0.037, ES = -0.26).  Almost 90% of parents were 
satisfied with melatonin for the improvement of sleep-onset problems, 70.8% for improved daytime behaviours and 
60.9% for improvement of mood. The authors concluded that melatonin improved chronic SOI in children with 
ADHD only as long as treatment was continued but did not cure it. 
Ayyash et al. 65 subjectively assessed the effects of melatonin on sleep latency and night-time awakening in children 
with neurodevelopmental disorders (ADHD, autism spectrum disorder or intellectual disability) in an observational 
study. The increase in the mean (± SD) for total sleep time (hours/night) in children with ADHD only was 2.68 ± 
1.22, (p<0.001), for sleep latency the mean decrease was 1.24 ± 1.20 hours, (p<0.02) and for awakening 
(number/night) the mean decrease was 0.23 ± 0.22, (p<0.02). Significant improvement in all three sleep problems 
was observed via sleep diaries. 
 
3.3.3 Zolpidem  
Blumer et al. 32 evaluated the hypnotic efficacy of zolpidem compared with placebo in children with ADHD-
associated insomnia in an RCT. No significant difference in latency to persistent sleep (LPS) between the zolpidem 
group (-20.28 min) and placebo (-21.27 min) was detected at week 4. For actigraphic (objective) measures at week 4, 
the baseline-adjusted least square (LS) mean difference ± standard error (SE) for total sleep time (i.e., total sleep 
time minus baseline total sleep time) was 2.77±14.23 min,  (p=.8461), and for LPS was 1.55±110.37 min, (p=.8884), 
indicating no significant difference between the groups. On the basis of Clinical Global Impression-Improvement 
(CGI-I) child assessments (subjective measure), the zolpidem group showed greater improvement in child score, 
compared with the placebo group at week 4 with LS mean difference ± SE of 0.4 ± 0.200, (p=.0280). For Clinical 
Global Impression-Severity (CGI-S) child scores at week 4, the baseline-adjusted mean decrease was greater for the 
zolpidem as compared with placebo  with LS mean difference ± SE of -0.64 ± 0.230, (p=.0059). At week 4 and 8, 
CGI-I and CGI-S variables showed greater improvement with zolpidem for the 12-to-17-year age group but not for 
the 6-to-11-year age group. 
3.3.4 L-theanine 
Lyon et al. 33 investigated the efficacy of L-theanine on objective and subjective aspects of sleep quality in boys 
with ADHD in an RCT. The objective sleep-quality measures were actigraph watch data and the subjective sleep 
measure was the Paediatric Sleep Questionnaire (PSQ). The actigraphy results indicated that the percent of time 
spent in restful sleep was increased in the L-theanine group compared to the placebo group (p<0.05) and there were 
fewer nocturnal activities in the L-theanine group compared to the placebo group (p<0.05). A lower mean number of 
minutes spent awake after onset of sleep was found in the L-theanine as compared with placebo, although this did 
not quite reach  statistical significance (p<0.058). There was no significant difference between the groups for sleep 
latency or duration (p>0.05). The authors did not present the details of the PSQ data but stated that this did not 
correlate significantly to the objective data gathered from actigraphy, suggesting that parents were not particularly 
aware of the quality of their child’s sleep. 
3.3.5 Eszopiclone 
Sangal et al. 31 found no significant differences between eszopiclone (high or low dose) groups and the placebo 
groups in the change from baseline to week 12 on polysomnography-measured LPS in an RCT: for high-dose 
eszopiclone vs. placebo, (p=0.3749), and for low-dose eszopiclone vs. placebo, (p>0.9999). Assessment of 
secondary subjective measures (patient/parent reports on sleep-onset latency, total sleep time, wake time after sleep 
onset (WASO), number of awakenings after sleep onset and sleep quality) revealed no statistically significant 
differences on hierarchical statistical analysis.  
 
3.3.6 Guanfacine 
Rugino 34 found that in comparison to placebo guanfacine worsen certain sleep parameters. The total sleep time for 
treatment group decrease by 57.32 min (SD=89.17) in comparison to increase by 31.32 min (SD=59.54) in placebo 
group (p=.005), showing a statistically significant difference. The children in treatment group were awake for a 
mean of 4.19 more minutes per hour of sleep whereas the children with placebo were awake for a mean of 0.58 min 
less per hour of sleep, showing a significant difference. Later onset of persistent sleep by 10.54±88.44 min was seen 
in the treatment group compared with 19.94±54.12 min earlier with placebo however this difference did not reach 
statistical significance. No statistical significance was seen in time of persistent sleep and time of awakening 
between two groups. 
 
 
 
 
3.4 Tolerability/Safety of pharmacological agents 
3.4.1 Clonidine 
In the systematic chart review by Prince et al. 60 treatment-emergent adverse events (TEAEs) with clonidine were 
usually mild, occurring in 31% of patients, the most common being sedation and fatigue. In one child, clonidine was 
associated with depression, which resolved after discontinuation of the drug. In the case series reported by Wilens et 
al. 29 neither the cardiovascular nor central nervous system adverse reactions typical for clonidine were observed. 
 
3.4.2 Melatonin 
The TEAEs reported with melatonin have usually been mild and similar to those with placebo. Weiss et al. 11 
reported a single serious event of migraine. Van der Heijden et al. 30 reported no significant difference between the 
melatonin and placebo groups. Adverse events such as headache, hyperactivity, dizziness and abdominal pain were 
reported. Hoebert et al. 64 reported adverse events of sleep-maintenance insomnia, excessive morning sedation, 
decreased mood, headache, profuse perspiration and daytime laziness. Persistence of these events led to 
discontinuation of melatonin in three children. Mohammadi et al. 62 reported that there was no statistically 
significant difference between mean scores of adverse effects for melatonin  and placebo (p=0.686) based on 
stimulant drug side effect questionnaire; however, the study was not powered adequately to allow any definitive 
comment on this issue. The most common adverse events reported were irritability, loss of appetite, sadness, weight 
loss, headache and difficulty falling asleep.  
 
3.4.3 Zolpidem  
In the study by Blumer et al. 32 one or more TEAEs were reported in 62.5% of the zolpidem-treated group and 
47.7% of the placebo-treated group. The TEAEs included dizziness, headache and hallucination. Administration was 
discontinued permanently because of TEAEs in 10 patients in the zolpidem group, compared with none in the 
placebo group. The main TEAE leading to discontinuation of zolpidem was hallucination, which occurred in 10 of 
136 patients. 
 
3.4.4 L-theanine 
Only one minor TEAE (facial tic) was observed for patients treated with L-theanine in the study by Lyon et al. 33. 
The event causality was deemed unlikely by the principal investigator. No other TEAEs were noted. 
 
3.4.5 Eszopiclone 
In the study by Sangal et al. 31 TEAEs were reported for 61.0%, 59.5% and 46.0% of the patients receiving high-
dose eszopiclone, low-dose eszopiclone and placebo, respectively. The most commonly reported TEAEs with 
eszopiclone were headache, dysgeusia and dizziness. Reported TEAEs of special interest included skin reaction, 
hallucination and suicidality. The open-label extension for this RCT demonstrated that eszopiclone was generally 
well tolerated for up to one year. Several patients discontinued treatment due to hallucinations and suicidal ideation; 
the former was noted in 2.3% and the latter in 1% of eszopiclone-treated patients.  
 
3.4.6. Guanfacine 
In this study Rugino 34 reported treatment-emergent somnolence in 73% of children in treatment group as compared 
to 6% in placebo group. No electrocardiographic, laboratory, growth, or vital sign parameter was statistically 
significantly different between the two groups. 
4 DISCUSSION 
To our knowledge, this is the first systematic review assessing the quality of studies of pharmacological treatments 
for behavioural insomnia in children with ADHD. Based on the results from the methodological quality assessment, 
only one high-quality study (RCT on eszopiclone31 was identified. Except for the RCT on eszopiclone 31 and an 
observational study on melatonin 64, the rest of the studies scored moderate to low on quality, reflecting a number of 
issues, including high risk of bias (due to poor methodological quality), inconsistency (due to the high degree of 
heterogeneity between studies) and inaccuracy/unreliability (due to the low numbers of participants). 
In most of the studies, the determination of behavioural insomnia was based on small sample sizes using subjective 
measures (parental reports, Somnologs or questionnaires) rather than more precise objective measures, using 
actigraphy. The retrospective chart review on clonidine by Prince et al. 60 was subject to observer bias. The small 
research letter by Tjon Pian Gi et al. 63 on melatonin did not provide sufficient details on study methodology, 
diagnosis of sleep insomnia or patient characteristics. No randomization or blinding was performed and 
consequently a placebo effect could not be excluded. In the Weiss et al. 61 study on melatonin, the effect of sleep 
hygiene could not be isolated from the effect of the melatonin. Although this is a relatively minor issue, the criterion 
for SOI in the study by Van der Heijden et al. 30 on melatonin was based on a Dutch child population and may not be 
generalizable to other population groups. A more important issue was that a considerable amount (31%) of data 
were missing, implying limitations to the data analysis and potential bias.  
The Hoebert et al. 64 study on melatonin lacked a long-term placebo arm and the questionnaire lacked information 
regarding concomitant medication. In the Mohammadi et al. 62 study on melatonin, the confounding effect of 
methylphenidate could not be excluded. Lyon et al. 33 studied the effect of the drug L-theanine in boys only. The 
results for guanfacine cannot be generalised due to unequal sample sizes at baseline and early termination of study 34. 
Given the high prevalence and compelling impact of behavioural insomnia in these children, there is a need for 
effective pharmacological agents with strong evidence. There is currently insufficient evidence to allow firm 
recommendations to be made with regard to the prescription of these pharmacological agents, due to a lack of high-
quality published studies; however melatonin, has showed consistent positive results. Zolpidem, eszopiclone and 
guanfacine showed unremarkable results by worsening different sleep parameters when compared with placebo. 
Although there are RCTs on the use of melatonin, zolpidem, eszopiclone, L-theanine and guanfacine for sleep-onset 
delay, the small number and the limitations of these RCTs imply that there is inadequate evidence on efficacy, 
effectiveness and safety. We note that a formal meta-analysis could not be performed due to the low quality and 
heterogeneous nature of the studies. 
 
4.1 Additional limitations 
Sleep issues in children with ADHD can be affected by a number of additional variables which may be confounding 
factors in the assessment of efficacy or adverse effects of medication used to treat behavioural insomnia. These 
include the following. 
First, ADHD is not a single condition but is a group of conditions with certain core features in common, typically 
poor concentration, over activity and impulsivity. Against this background it is not surprising that a drug that is 
effective in treating ADHD in one child may be ineffective in another; similarly, it would not be surprising if a drug 
that was effective in treating sleep in one child with ADHD was ineffective in another. In particular, there is a 
subgroup of children with ADHD in whom sleep onset is improved with an evening dose of methylphenidate 
whereas, in most children, an evening dose of methylphenidate would delay sleep onset 68. 
Second, the medication used to treat ADHD may be a confounding factor when assessing drugs used to help with 
behavioural insomnia. Some medications that are frequently used to treat ADHD can delay sleep onset whereas 
others are either sleep neutral or may improve sleep. For example, methylphenidate or dexamfetamine typically 
delay sleep onset (except in the subgroup referred to in the previous paragraph) whereas other medications are sleep 
neutral or may improve sleep such as clonidine 69-71. This implies that the assessment of medications used to treat 
behavioural insomnia in children with ADHD should adjusted for co-medication used to treat the ADHD, which 
may not be easy to achieve. 
Third, ADHD is associated with a very high rate of comorbidities which may, in turn be associated with a high rate 
of sleep problems, which could affect the response to sleep medication. For example, autism spectrum disorder is 
associated with a high rate of ADHD and is also associated with a high rate of sleep disorders. Medications used to 
treat the comorbidities can also have a major effect on sleep. For example, risperidone used to treat anxiety and 
behavioural disorders in children with autism spectrum disorder and ADHD can improve sleep 72. 
Fourth, sleep is highly dependent on environmental factors 73. Proper attention to sleep hygiene should minimise the 
confounding effects of such factors but may not eliminate them completely. 
Finally, we limited our search to papers in English. 
4.2 Implications 
Our systematic review suggests that, with the possible exception of melatonin, there is generally an insufficient 
evidence base for the use of medications in treating sleep-related disturbances such as insomnia in ADHD. It was 
also seen that zolpidem, eszopiclone and guanfacine did not show significant improvement in different sleep 
parameters when compared with placebo. Considering that there are currently no FDA drugs approved for the 
treatment of sleep disturbance in children with ADHD, clinicians should discuss the limitations of available 
evidence carefully with the patient and the family, aiming for a short period of treatment, should a trial with a 
pharmacological intervention be agreed. 
Further high-quality research is required, as these medications appear to be widely used despite the lack of long-
term data on benefits or risks. Future research should include RCTs with sufficient sample size, using both objective 
and subjective outcome measures. They should be powered adequately to yield statistically meaningful results of the 
measures of interest. These studies should evaluate the effect of pharmacological agents not only on the sleep-
associated disturbances but also on long-term daytime function, health and well-being.  
 
5 CONCLUSION 
Although some of the included studies reported similar conclusions of having a positive effect in improving 
behavioural insomnia, because of their low quality, small sample sizes and heterogeneous designs, the results cannot 
be viewed as reliable. Incontrovertible evidence establishing the definitive values of clonidine, melatonin, zolpidem, 
eszopiclone, L-theanine and guanfacine in treating ADHD-related behavioural insomnia in children does not appear 
to be available.  Further high-quality research and RCTs are required to evaluate the effectiveness and safety of 
these pharmaceutical agents in treating behavioural insomnia in children with ADHD. 
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 Table 1: Characteristic of included studies  
Study 
No. 
Study  Study Design 
ADHD 
Medications 
Age Inclusion criteria Exclusion Criteria Drug 
Sleep 
Outcome 
Measures 
Effects on Sleep Safety 
1 
Weiss57                                                                                                                                
2006                                                                     
(Canada) 
Randomised, 
double-blind,
placebo-
controlled 
crossover trial 
Stimulant 
medications 
6-14 
years 
Children with ADHD, initial 
insomnia of >60 min, taking 
stimulant medication with 
no change in dose for at 
least 2 months and willing to 
maintain the current dose for 
the duration of the protocol 
Children in stressful life 
circumstances that could 
account for new-onset sleep 
difficulties or unable to 
comply with sleep hygiene 
recommendations 
Melatonin/     
placebo                               
with                           
sleep 
hygiene                                                              
Parent-
completed 
Somnologs 
and actigraph  
Mean Somnolog SOL for melatonin was 
46.4 min compared to 62.1 min for 
placebo. More time asleep (15 min) was 
evident with melatonin than with 
placebo. Analysis of actigraphic 
measurement of total time asleep did not 
yield a significant treatment difference. 
Mild to moderate 
adverse events 
except migraine 
which was 
severe. 
2 
Van der 
Heijden30                                                                              
2007                                                             
(Netherlands) 
Randomised, 
double-blind, 
placebo-
controlled trial 
Medication
free  
6-12
years 
Children diagnosed with 
ADHD and SOI and written 
informed consent obtained 
from parents 
IQ<80; pervasive 
developmental disorder; 
chronic pain; known 
disturbed hepatic or renal 
function; epilepsy; earlier 
use of melatonin; use of 
stimulants, neuroleptics, 
benzodiazepines, clonidine, 
antidepressants, hypnotics or 
beta blocker within 4 weeks 
before enrolment 
Melatonin / 
placebo   
without   
sleep 
hygiene   
Actigraphy, 
DLMO and 
sleep logs  
Sleep onset advanced by 26.9 ± 47.8 min 
and mean total time asleep increased by 
19.8 ± 61.9 min with melatonin 
compared to delay of sleep onset time by 
10.5 ± 37.4 min and decrease of total 
sleep time of 13.6 ± 50.6 min with 
placebo. Melatonin group showed 
significant decrease in sleep latency. 
Advance in DLMO in melatonin treated 
group of 44.4 ± 67.9 min. 
Mild adverse 
events, almost 
similar in both 
the groups. No 
discontinuations 
or withdrawals. 
3 
Blumer32                           
2009                       
(United 
States) 
Randomised, 
double-blind 
placebo-
controlled, 
parallel-group 
trial 
Psychostimul
ant  
6-17 
years 
Children diagnosed with 
ADHD and complained 
about childhood insomnia 
and have latency to 
persistent sleep > 30 
minutes and a sleep 
disturbance not attributed to 
direct physiologic effect of 
an abused drug or misused 
prescription medication. 
Other sleep disorder 
diagnosed with baseline 
polysomnography; other 
major psychiatric disorders 
or a history of substance 
abuse or dependence; 
previous adverse experience 
with zolpidem; use of 
pharmacologic sleep aids 
that the patient was 
unwilling to discontinue; or 
current use of sertraline  
Zolpidem/ 
placebo 
without   
sleep 
hygiene   
Polysomnogra
phy, Clinical 
Global 
Impression 
Scales  
The latency to persistent sleep mean 
reduction from baseline was -20.28 
minutes with zolpidem and -21.27 
minutes with placebo. Analyses of 
secondary sleep measures at week 4 
showed no difference between groups 
but CGI scores based on interviews 
indicated favourable effects of zolpidem 
in adolescent. 
62.5% of 
zolpidem-treated 
patients and 
47.7% of placebo 
treated patients 
experienced ≥ 1 
TEAE, including 
dizziness, 
headache and 
hallucinations. 
4 
Lyon33                         
2011                                                                                   
(Canada) 
Randomised, 
double-blind, 
placebo-
controlled 
clinical trial 
27 on 
Stimulant 
medication 
and 64 were 
medication 
free 
8-12 
years 
Boys with ADHD  
Psychiatric and medical 
conditions that (1) could 
result in an inappropriate 
diagnosis of ADHD, or (2) 
were not congruent with 
exclusion criteria; other 
psychiatric diagnosis; any 
chronic medical condition; 
serious learning disability; 
or attendance in a behaviour 
modification program   
L-theanine/  
placebo 
without   
sleep 
hygiene   
Actigraphy 
and paediatric 
sleep 
questionnaire  
Increased percentage of time spent in 
restful sleep in L-theanine compared to 
placebo group for actigraph-measured 
sleep efficiency. Fewer bouts of 
nocturnal activity with L-theanine 
compared to placebo. Lower number of 
minutes spent awake after onset of sleep 
in L-theanine compared to placebo 
(p<0.058) .No significant difference for 
sleep latency or sleep duration (p>0.05). 
PSQ data did not significantly correlate 
with the actigraphic data.  
L-theanine at 
relatively high 
doses was well 
tolerated. One 
minor adverse 
event of subtle 
facial tic was 
noted in L-
theanine group, 
leading to 
discontinuation. 
5 
Mohammadi58                                                                                   
2012                                                                                                   
(Iran) 
Randomised, 
double-blind, 
placebo-
controlled 
clinical trial 
Methylpheni
date 
7-12 
years 
Children diagnosed with 
ADHD and did not use any 
confounding drugs or 
supplements 
Children with history of 
major prenatal 
complications; any past or 
present psychosis; comorbid 
Tourette syndrome; celiac; 
phenylketonuria; autism or 
other persistent 
developmental disorder; 
narcotic use 
Melatonin/        
placebo                    
+  
Ritalin 
without   
sleep 
hygiene      
SDSC sleep 
questionnaire  
Increase in mean total sleep duration 
(hours) with melatonin from 8 to 8.51 
compared to decrease with placebo from 
8.77 to 8.27. Decrease in mean sleep 
latency (min) with melatonin from 23.15 
to 17.96 compared to increase with 
placebo from 21.37 to 26.37.  
Mean side-effect 
scores in 
melatonin group 
was 11.35 ± 8.81 
and 10.16 ± 9.05 
in placebo group.  
6 
Sangal31                                                                               
2014                                                                          
(USA) 
Randomised, 
double-blind, 
placebo-
controlled trial 
followed by 2-
week single-
blind washout 
period 
Amphetamin
e or 
Atomoxetine 
or 
Dexampheta
mine or 
Lisdexamfet
amine or 
Methylpheni
date or 
Dextroamph
etamine/amp
hetamine 
 
aged 
6-11
and 
12-17 
years 
Children diagnosed with 
ADHD and complaints of 
insomnia (latency to 
persistent sleep > 30 min or 
wake time after sleep > 45 
min determined by baseline 
PSG) 
Another primary sleep 
disorder; other major 
psychiatric disorders 
(bipolar I/II disorder, major 
depression, conduct 
disorder, generalized anxiety 
disorder); current alcohol or 
substance abuse or history 
of abuse within 3 months of 
study participation; tobacco 
and nicotine use within 3 
months of study 
participation 
Eszopiclone 
/ Placebo 
without   
sleep 
hygiene      
Wrist 
actigraphy, 
CGI-severity 
and child 
scales such as 
PDSS  
No significant difference between 
eszopiclone (low-dose or high-dose) 
groups and placebo group in change of 
LPS from baseline to week 12. The mean 
difference for LPS between high dose 
eszopiclone vs placebo was 7.33 min and 
for low dose vs placebo was 2.21 min. 
TEAEs were 
reported by 61%, 
59.5% and 46% 
of patients 
receiving high-
dose, low-dose 
and placebo, 
respectively. 
Most common 
were headache, 
dysgeusia and 
dizziness.  
Open-label 
follow-up 
study 
Eszopiclone 
without   
sleep 
hygiene      
7 
Wilens29                                                       
1994                                                        
(USA) 
Case series -
4-17 
years 
Spontaneous or drug-
induced sleep disturbances 
in children with ADHD 
Not specified 
Clonidine 
without   
sleep 
hygiene                                                                                                                      
Child and 
parent 
responses  
Clonidine exerted somnolent properties 
within 30 minutes and effect persisted 
until morning. 
No unusual 
adverse effects 
8 
Prince56                                                                      
1996                                                                 
(USA) 
Systematic 
chart review 
Stimulants or 
tricyclic 
antidepressa
nt or mood 
stabilizers or 
selective
serotonin
reuptake 
inhibitors or 
antipsychotic
s or 
antihistamine
s 
4-18 
years 
Patients being treated with 
clonidine for ADHD-
associated sleep disturbance 
for at least 1 week 
Not specified 
Clonidine 
without   
sleep 
hygiene                                                                                                                                                                               
CGS  
Pre-clonidine CGS = 5.1 +/- 0.02; post-
clonidine CGS = 2.6 +/- 0.01. 
Generally mild 
adverse effects 
occurred in 31% 
(N=19) patients, 
most common 
being morning 
sedation and 
fatigue; others 
included 
worsening sleep, 
severe 
nightmares and 
depression which 
resolved on 
discontinuation. 
9 
Tjon Pian Gi59                                                                                                 
2003                                                                       
(Netherlands)                                  
Observational
study (open
label study)
Methylpheni
date 
Not
specif
ied 
Children diagnosed with 
ADHD with prescribed 
methylphenidate.  
Incorrect recording of data 
Melatonin 
without   
sleep 
hygiene                                                                                                                                                                                     
Clinical 
interviews and 
psychological 
tests before 
and after
medication. 
Short-term effect: improved sleep onset 
(15-240 min); long-term effect: 
improved sleep onset (15-64 min) 
Relapse of insomnia when melatonin 
forgotten during study (n=2) and after
ending study (n=2). 
Restless sleep 
(n=1) 
10 
Hoebert60                                                                                   
2009                                              
(Netherlands) 
Observational 
study (long-
term follow-
up study) 
Medication 
free 
6-12 
years 
Children with diagnosis of 
ADHD and SOI and a total 
IQ >80 
Same as for Van der Heijden 
Melatonin 
without   
sleep 
hygiene                                                                                                                      
Questionnaire 
consisting of 
19 multiple-
choice, 
numeric, 
open-ended
and scaled 
questions. 
9% discontinued melatonin completely 
because of total improvement in sleep-
onset insomnia. Long-term treatment was 
effective for sleep problems in 88% of 
cases.  
19 (20.2%) of 
children 
experienced 
adverse events, 
10 (52.6%) 
children had self-
limiting adverse 
events and N=6 
(31.6%) had 
persistent 
adverse. N=7 
(7.4%) parents 
reported unusual 
co-morbidity. 
11 
Rugino34                  
2014 
(USA) 
Randomised, 
double-blind, 
placebo-
controlled 
clinical trial 
Medication 
free 
6-12 
years 
Children with self- or 
parent-reported concern 
with sleep duration or 
quality despite adequate 
sleep hygiene practices and 
caffeine restriction, 
The body mass index < fifth 
percentile for age or if the 
body weight was >80 kg. 
Clinically significant 
psychiatric pathology, such 
as ASD, major depression, 
etc. Clinically significant 
medical conditions such as 
hepatic, neurologic, 
hemodynamic, cardiac, or 
renal dysfunction (including 
clinically significant 
electrocardiographic 
findings), or with clinically 
significant laboratory 
findings. Obstructive sleep 
apnea and periodic limb 
movement. 
Guanfacine 
with sleep 
hygiene 
Polysomnogra
phy 
Total sleep time, was shorter in 
guanfacine in contrast to placebo 
(−57.32, SD = 89.17 vs. +31.32, SD = 
59.54 min, p = .005). There are no 
statistical differences in time onset of 
persistent sleep and awakening between 
the two groups (p>0.05). 
Somnolence was 
the most 
common adverse 
event with 
guanfacine (8/11, 
73%) as 
compared to 
placebo (1/16, 
6%).  
12 
Ayyash65                                                                                                                   
2015                                                     
(United 
Kingdom) 
Observational 
study 
Psychostimul
ants 
mean 
age 
6.3 ± 
1.7 
years 
Children with diagnosis of 
ADHD, ASD or ID with 
severe sleep problems and 
who had failed to respond to 
behavioural-management 
strategies 
Children with diagnosis of 
obstructive sleep apnoea or 
nocturnal seizures 
Melatonin 
without   
sleep 
hygiene      
Structured 
sleep diaries  
Melatonin treated children showed 
improvement in total sleep time 
(hours/night), sleep-onset delay and 
number of awakenings (n/night). 
No serious event 
in ADHD group 
*Abbreviations: ADHD-attention deficit hyperactivity disorder; ASD-autism spectrum disorder; CGI-clinical global assessment of improvement, CGS-clinical global assessment of sleep severity, DLMO-dim light 
melatonin onset; ID-intellectual disability;  IQ-intelligence quotient; LPS-latency to persistent sleep; PDSS-pediatric daytime sleepiness scale; PSG-polysomnography, PSQ- Paediatric Sleep Questionnaire; SDSC-sleep 
disturbance scale for children; SOI-sleep onset insomnia; SOL-sleep onset latency; TEAE-treatment-emergent adverse effect 
Table 2 CONSORT Scores for RCT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Drugs 
Title 
and 
abstract 
(/1) 
Introduction 
(/1) 
Methods 
(/5) 
Randomization 
(/5) 
Results 
(/7) 
Discussion 
(/3) 
Other 
information 
(/3) 
Total 
(/25) 
  
Weiss61                       
2006 
Melatonin 0.5 1 3.5 3 3.5 3 1 15.5 
Van der 
Heijden30                                                                             
2007                                                              
Melatonin 0.5 1 3.5 3.5 5 3 2 18.5 
Mohammadi62                      
2012 
Melatonin 1 1 1 2 2.5 2 1 10.5 
Blumer32                                                            
2009 
Zolpidem 1 1 4 3 5.5 2 1 17.5 
Lyon33             
2011 
L-theanine 1 1 3 2 1.5 0 1 9.5 
Sangal31                       
2014 
Eszopiclone 0.5 1 4 4 6 3 3 21.5 
Rugino34                       
2014 
Guanfacine 0.5 1 4 1 6 2 3 17.5 
Table 3 Quality Scores for Observational studies  
Study Drugs 
Reporting 
(/11) 
External 
Validity                                                         
(/10) 
Internal 
Validity                                
(/6) 
Power                                       
(/1) 
Total 
Quality
Score 
(/28) 
  
Wilens29                        
1994 
Clonidine 4 0 0 0 4 
Prince56                           
1996 
Clonidine 8 3 2 0 13 
Tjon Pian Gi59                                 
2013 
Melatonin 7 2 2 0 11 
Hoebert60                          
2009 
Melatonin 9 7 6 0 22 
Ayyash61                                 
2015 
Melatonin 8 4 2 0 14 
 
